Ovarian Cancer GOG 1861

March 13, 2013

Location: The Hospital of Central Connecticut

A Randomized Phase II Evaluation of Single-Agent Bevacizumab and Combination Bevacizumab with Fosbretabulin Thromethamine in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma (Platinum Sensitive and Platinum Resistant are eligible-NO Refractory patients).

Connect With Us

Subscribe to Our Newsletters

Get the latest healthcare news directly in your inbox.

Hartford HealthCare Offices

One State Street, Suite 19, Hartford, CT 06103 • Contact Us

Donations to Hartford HealthCare are managed by the Hartford Hospital Department of Philanthropy, a Connecticut tax-exempt organization under section 501(c)(3) of the IRS code (E.I.N. 06-0646668). For more information, click here.